Globalworld globe
United Kingdom
North America
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

MVP signs exclusive Penthrox deal for China

Oct 7, 2018Mark EdwardsNews

8 October 2018

ASX Announcement

MVP signs exclusive Penthrox deal for China with Daiichi Sankyo

Medical Developments International Limited (ASX: MVP) is delighted to announce it has entered into an exclusive Distribution and License Agreement with Daiichi Sankyo Company Limited (Daiichi Sankyo) for Penthrox? in China, Thailand and Vietnam. Daiichi Sankyo is listed on the Tokyo Stock Exchange (TSE: 4568)

Under the terms of the Agreement, Daiichi Sankyo will pay MVP up to $32.5 million US dollars (USD) (AUD $45.8m), including US$15 million upfront (AUD $21.1m), and sales-based milestone payments.

For further details please refer to the following link – ASX Announcement – (Penthrox – China)

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

  • EU Transition and Trading Update

    3 December 2020 ASX ANNOU...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.